Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Trends in Engagement With Opioid Use Disorder Treatment Among Medicaid Beneficiaries During the COVID-19 Pandemic
Alyssa Shell Tilhou, Laura Dague, Brendan Saloner, et al.
JAMA Health Forum (2022) Vol. 3, Iss. 3, pp. e220093-e220093
Open Access | Times Cited: 27

Showing 1-25 of 27 citing articles:

Pandemic telehealth flexibilities for buprenorphine treatment: a synthesis of evidence and policy implications for expanding opioid use disorder care in the United States
Noa Krawczyk, Bianca Rivera, Carla King, et al.
Health Affairs Scholar (2023) Vol. 1, Iss. 1
Open Access | Times Cited: 16
Changes in Buprenorphine and Methadone Supplies in the US During the COVID-19 Pandemic
Annie Y. Chen, David Powell, Bradley D. Stein
JAMA Network Open (2022) Vol. 5, Iss. 7, pp. e2223708-e2223708
Open Access | Times Cited: 17
Substance-induced mental disorders and discontinuation of medication for opioid use disorder
Alyssa Shell Tilhou, Richard A. Grucza, Kevin Y. Xu
Drug and Alcohol Dependence (2025), pp. 112685-112685
Closed Access
Trends in Opioid Use Disorder Outpatient Treatment and Telehealth Utilization Before and During the COVID-19 Pandemic
Kayla N. Tormohlen, Matthew D. Eisenberg, Michael Fingerhood, et al.
Psychiatric Services (2023) Vol. 75, Iss. 1, pp. 72-75
Open Access | Times Cited: 7
Patients’ and Clinicians’ Experiences with In-person, Video, and Phone Modalities for Opioid Use Disorder Treatment: A Qualitative Study
Tamar Wyte‐Lake, Deborah J. Cohen, Shannon Adair Williams, et al.
Journal of General Internal Medicine (2024) Vol. 39, Iss. 12, pp. 2179-2186
Closed Access | Times Cited: 2
Medicaid professional fees for treatment of opioid use disorder varied widely across states and were substantially below fees paid by medicare in 2021
Lisa Clemans-Cope, Victoria H. Lynch, Maya Payton, et al.
Substance Abuse Treatment Prevention and Policy (2022) Vol. 17, Iss. 1
Open Access | Times Cited: 10
Buprenorphine Treatment Episodes During the First Year of COVID: a Retrospective Examination of Treatment Initiation and Retention
Bradley D. Stein, Rachel K. Landis, Flora Sheng, et al.
Journal of General Internal Medicine (2022) Vol. 38, Iss. 3, pp. 733-737
Open Access | Times Cited: 10
Enumerating contributions of fentanyls and other factors to the unprecedented 2020 rise in opioid overdose deaths: model-based analysis
Erin J. Stringfellow, Tse Yang Lim, Catherine DiGennaro, et al.
PNAS Nexus (2023) Vol. 2, Iss. 4
Open Access | Times Cited: 6
Pandemic telehealth flexibilities for buprenorphine treatment: A synthesis of evidence and policy implications for expanding opioid use disorder care in the U.S
Noa Krawczyk, Bianca Rivera, Carla King, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 6
Impact of the COVID-19 pandemic on treatment for mental health needs: a perspective on service use patterns and expenditures from commercial medical claims data
Ta‐Hsin Li, Leah Kamin, Judy George, et al.
BMC Health Services Research (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 5
Use of Telehealth for Opioid Use Disorder Treatment in Safety Net Primary Care Settings: A Mixed-Methods Study
Steffani R. Bailey, Tamar Wyte‐Lake, Jennifer Lucas, et al.
Substance Use & Misuse (2023) Vol. 58, Iss. 9, pp. 1143-1151
Closed Access | Times Cited: 5
Association of buprenorphine retention and subsequent adverse outcomes following non-fatal overdose: An analysis using statewide linked Maryland databases
Olivia K. Sugarman, Brendan Saloner, Thomas M. Richards, et al.
Drug and Alcohol Dependence (2024) Vol. 258, pp. 111281-111281
Closed Access | Times Cited: 1
National- and State-Level Pharmacy-Based Buprenorphine Dispensing, United States 2019–2021
Chase L. Barham, Andrea E. Strahan, Kun Zhang, et al.
Journal of General Internal Medicine (2024) Vol. 39, Iss. 10, pp. 1951-1953
Closed Access | Times Cited: 1
Telehealth and disparities in opioid use disorder treatment: Medicaid enrollees versus privately insured individuals
Lindsay Allen, Melinda Xu
Health Services Research (2024) Vol. 60, Iss. 1
Open Access | Times Cited: 1
Retrospective study investigating naloxone prescribing and cost in US Medicaid and Medicare patients
Christopher D. Manko, Mohamed S Ahmed, Lavinia R Harrison, et al.
BMJ Open (2024) Vol. 14, Iss. 5, pp. e078592-e078592
Open Access | Times Cited: 1
Perceptions of COVID-19 risk during the pandemic: perspectives from people seeking medication for opioid use disorder
Sarah E. Clingan, Sarah J. Cousins, Chunqing Lin, et al.
Annals of Medicine (2023) Vol. 55, Iss. 1, pp. 480-489
Open Access | Times Cited: 2
Urine drug testing among Medicaid enrollees initiating buprenorphine treatment for opioid use disorder within 9 MODRN states
Lindsey R. Hammerslag, Jeffery Talbert, Julie M. Donohue, et al.
Drug and Alcohol Dependence (2023) Vol. 250, pp. 110875-110875
Open Access | Times Cited: 2
Navigating Addiction Treatment During COVID-19: Policy Insights from State Health Leaders
Sarah White, Alexander D. McCourt, Kayla N. Tormohlen, et al.
Health Affairs Scholar (2024) Vol. 2, Iss. 2
Open Access
How Does Telehealth Expansion Change Access to Healthcare for Patients With Different Types of Substance Use Disorders?
Alyssa Shell Tilhou, Marguerite Burns, Preeti Chachlani, et al.
Substance Use & Addiction Journal (2024) Vol. 45, Iss. 3, pp. 473-485
Open Access
Can telehealth expansion boost health care utilization specifically for patients with substance use disorders relative to patients with other types of chronic disease?
Alyssa Shell Tilhou, Laura Dague, Preeti Chachlani, et al.
PLoS ONE (2024) Vol. 19, Iss. 4, pp. e0299397-e0299397
Open Access
Quantifying diagnosis and treatment practices of opioid use disorder in primary care practices using chart review data
Elisabeth Callen, Tarin Clay, Cory Lutgen, et al.
Journal of Addictive Diseases (2024) Vol. 43, Iss. 1, pp. 59-66
Closed Access
Impact of the COVID-19 pandemic on health care utilization for commercial and Medicaid beneficiaries with opioid use disorder
Lavonia Smith LeBeau, Michael A. Head, Rachel Mosher Henke, et al.
Addiction Research & Theory (2024), pp. 1-9
Closed Access
Methadone treatment utilization and overdose trends among Medicaid beneficiaries in New Jersey before and during the COVID-19 pandemic
James F. Lloyd, Peter Treitler, Jamey J. Lister, et al.
Journal of Substance Use and Addiction Treatment (2024) Vol. 167, pp. 209476-209476
Open Access
Ratio of emergency department visits to deaths for opioid overdose
Himani Byregowda, Ryoko Susukida, Masoumeh Amin‐Esmaeili, et al.
Injury Prevention (2024), pp. ip-045116
Open Access
Assessment of COVID-19–Driven Changes in an Integrated OBGYN-Addiction Treatment Clinic and Future Implications
Sumaya Smarony, Anna Beth Parlier‐Ahmad, Hannah Shadowen, et al.
Journal of Addiction Medicine (2022) Vol. 17, Iss. 3, pp. e183-e191
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top